This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for LVHD
Why Is Pfizer (PFE) Up 1.6% Since Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer (PFE) & BioNTech Get CHMP Nod for Updated Covid-19 Jab
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech receive a positive recommendation from the CHMP for its Omicron XBB.1.5-adapted Covid-19 vaccine.
Novo Nordisk's (NVO) Shares Jump 17% in a Month: Here's Why
by Zacks Equity Research
Novo Nordisk's (NVO) commercial and pipeline progress with its popular obesity drug, Wegovy, continues to drive the share price momentum.
Pfizer's (PFE) RSV Vaccine Abrysvo Gets Approval in EU
by Zacks Equity Research
Pfizer's (PFE) RSV vaccine, Abrysvo, gets approval in Europe to protect infants through maternal immunization as well as for older adults.
Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation
by Kinjel Shah
FDA and EU approve Pfizer's (PFE) RSV vaccine, Abrysvo for maternal immunization. J&J (JNJ) finalizes separation of its Consumer Health company, Kenvue.
Novavax (NVAX) Updated COVID Jab Effective Against Eris Variant
by Zacks Equity Research
In studies on small animals and primates, Novavax's (NVAX) updated monovalent COVID-19 vaccine generates a robust immune response against the currently dominating Eris variant.
The Zacks Analyst Blog Highlights Moderna, BioNTech, Novavax and Pfizer
by Zacks Equity Research
Moderna, BioNTech, Novavax and Pfizer are included in this Analyst Blog.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
U.S. Govt to Urge Citizens to Get New COVID-19 Shots
by Zacks Equity Research
Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.
Pfizer's (PFE) RSV Vaccine Gets FDA Nod for Pregnant Women
by Zacks Equity Research
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for the prevention of lower respiratory tract disease in infants through administration to pregnant women.
Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant
by Zacks Equity Research
Moderna's (MRNA) updated monovalent COVID-19 vaccine generates a robust immune response against the dominating Eris variant and another rapidly spreading virus strain in a clinical study.
Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug
by Kinjel Shah
FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.
AbbVie (ABBV) Gets EU Approval for Migraine Prevention Drug
by Zacks Equity Research
Following the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU to prevent episodic and chronic migraines.
The Zacks Analyst Blog Highlights Broadcom, Pfizer, Advanced Micro Devices, Charles Schwab, Canadian National Railway and D.R. Horton
by Zacks Equity Research
Broadcom, Pfizer, Advanced Micro Devices, Charles Schwab, Canadian National Railway and D.R. Horton are included in this Analyst Blog.
Top Analyst Reports for Broadcom, Pfizer & AMD
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Pfizer Inc. (PFE) and Advanced Micro Devices, Inc. (AMD).
Pfizer's (PFE) New Multiple Myeloma Drug Elrexfio Gets FDA Nod
by Zacks Equity Research
The FDA's accelerated approval of Pfizer's (PFE) new multiple myeloma drug Elrexfio/elranatamab is based on data from the pivotal phase II MagnetisMM-3 study.
Novo Nordisk (NVO) Rides on Ozempic & Wegovy Amid Rivalry
by Zacks Equity Research
Novo Nordisk (NVO) continues to witness increasing demand for its diabetes and obesity care products like Ozempic, Wegovy and Rybelsus amid rising competition from other pharma bigwigs.
Can Moderna (MRNA) Diversify Beyond Its COVID-19 Jab Sales?
by Zacks Equity Research
With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next three years.
Pfizer (PFE) Seems Well-Poised for Long-Term Growth: Here's How
by Zacks Equity Research
Though Pfizer's (PFE) revenues from COVID products are declining sharply, it is set to launch some key non-COVID products in 2023, which can drive long-term sales and profit growth.
Pharma ETFs in Focus Post Q2 Earnings
by Sweta Killa
Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.
Here's Why Investors Should Buy These 2 Medical Stocks After Earnings
by Shaun Pruitt
Following their favorable Q2 reports now looks like a good time to buy Encompass Health (EHC) and Vertex Pharmaceuticals (VRTX) stock.
Pfizer's (PFE) Q2 Earnings Beat, Sales Miss, Stock Declines
by Zacks Equity Research
Pfizer (PFE) beats estimates for second-quarter earnings but misses the same for sales. It trims the upper end of its revenue guidance range for 2023. Stock falls.